Jo Chien

Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)

Laura A. Huppert, Reshma Mahtani, Samantha Fisch et al. · npj Breast Cancer · 2025 · 26 citations · Full text

Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Angela DeMichele, Stacy L. Moulder, Meredith Buxton et al. · Cancer Research · 2016 · 17 citations

Her2+ Breast Cancer, Breast Oncology, Pcr Rate +14

Abstract PS08-04: Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)

Laura A. Huppert, Reshma Mahtani, Samantha Fisch et al. · Cancer Research · 2024 · 15 citations

Breast Oncology, Most Pts, Pathology +20

Abstract GS5-03: Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Claudine Isaacs, Rita Nanda, Jo Chien et al. · Cancer Research · 2023 · 14 citations

Breast Oncology, Cemiplimab 350, Immunology +19

Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Meredith Buxton, Angela DeMichele, Stephen Chia et al. · Cancer Research · 2016 · 10 citations

Her2+ Breast Cancer, Surgical Oncology, Breast Oncology +13